Sirtex Medical soars

Sirtex Medical (ASX: SRX) was one of the best performing stocks in the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) during the last financial year with its share price soaring from just over $6 to nearly $12, providing shareholders with a return of 97% for the 12 months.

Sirtex’s growing share price was in response to strong increases in sales of its SIR-Spheres, which are an innovative form of radiation therapy for treating liver cancer. Growing sales volumes look set to continue with today’s announcement that dose sales grew 13.1% in the fourth quarter. Sirtex has now had 36 consecutive quarters of dose sales growth!

Investing in the biotech sector is not for the fainthearted however, with last financial year seeing some previously high flying biotech shares fall significantly. Respiratory disease drug maker Pharmaxis’s  (ASX: PXS) share price plunged around 85% in response to regulatory issues, while promising diversified biotech Starpharma Holdings (ASX: SPL) lost over 30% as some investors became concerned by results from a Phase 2 trial.

Foolish takeaway

Investing in the biotech sector is rarely smooth sailing and many great ideas never make it to market. For those medicines that do, the returns for patient investors can be stellar, as Sirtex Medical proves.

Looking to cure your portfolio by adding some high yielding ASX shares? Get “3 Stocks for the Great Dividend Boom” in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

Top 3 ASX Blue Chips To Buy For 2019

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked…

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of The Motley Fool’s Top 3 Blue Chip Stocks for 2019.

Each one pays a fully franked dividend. The names of these Top 3 ASX Blue Chips are included in a specially prepared FREE report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

See the 3 blue chip stocks

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.